Source facts
FDA issued an approval letter for LOARGYS on 2026-02-24. The source metadata identifies BLA 761211 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
LOARGYS — FDA Approval Letter (BLA 761211)
Issued to IMMEDICA PHARMA AB. Application is approved as submitted.
Issued
February 24, 2026Application
BLA • 761211
Product
LOARGYS
Company
IMMEDICA PHARMA AB
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for LOARGYS?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: BLA 761211.
- 3Submission: original application.
- 4Sponsor: IMMEDICA PHARMA AB.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the LOARGYS approval letter
Is LOARGYS FDA approved?
This letter documents an FDA approval action: FDA approved BLA 761211 for LOARGYS, sponsored by IMMEDICA PHARMA AB, on February 24, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is BLA 761211?
BLA 761211 is the application under which FDA issued this approval letter for LOARGYS to IMMEDICA PHARMA AB. The letter is dated February 24, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.